Fisher Wallace electrocutes the bioelectronics market

November 25, 2019 | Case Study

Fisher Wallace is a company best known for late-night infomercials on both television and YouTube channels for a product that treats depression, chronic pain, and insomnia with electricity. Specifically, the company uses transcranial alternating current stimulation (tACS) in the form of a proprietary waveform to alter the electrical signals in the brain. Unfortunately, despite numerous clinical trials, there has been no validation of any claims, and the company has instead leaned on a misleading marketing approach to try to convince consumers of the product's efficacy. In fact, Fisher Wallace has lobbied to ensure that the FDA did not move to reclassify surface bioelectronic devices as class III instead of class II, which would have required a premarket approval (PMA) process that would have required clinical proof of efficacy. 

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978